PT  - JOURNAL ARTICLE
AU  - Qi, Xiaolong
AU  - Liu, Yanna
AU  - Fallowfield, Jonathan A.
AU  - Wang, Jitao
AU  - Wang, Jianwen
AU  - Li, Xinyu
AU  - Shi, Jindong
AU  - Pan, Hongqiu
AU  - Zou, Shengqiang
AU  - Zhang, Hongguang
AU  - Chen, Zhenhuai
AU  - Li, Fujian
AU  - Luo, Yan
AU  - Mei, Mei
AU  - Liu, Huiling
AU  - Wang, Zhengyan
AU  - Li, Jinlin
AU  - Yang, Hua
AU  - Xiang, Huihua
AU  - Li, Xiaodan
AU  - Liu, Tao
AU  - Zheng, Ming-Hua
AU  - Liu, Chuan
AU  - Huang, Yifei
AU  - Xu, Dan
AU  - Li, Xiaoguo
AU  - Kang, Ning
AU  - He, Qing
AU  - Gu, Ye
AU  - Zhang, Guo
AU  - Shao, Chuxiao
AU  - Liu, Dengxiang
AU  - Zhang, Lin
AU  - Li, Xun
AU  - Kawada, Norifumi
AU  - Jiang, Zicheng
AU  - Wang, Fengmei
AU  - Xiong, Bin
AU  - Takehara, Tetsuo
AU  - Rockey, Don C.
AU  - ,
TI  - Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study
AID  - 10.1101/2020.04.24.20072611
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.24.20072611
4099  - http://medrxiv.org/content/early/2020/04/28/2020.04.24.20072611.short
4100  - http://medrxiv.org/content/early/2020/04/28/2020.04.24.20072611.full
AB  - Background Patients with pre-existing cirrhosis are considered at increased risk of severe coronavirus disease 2019 (COVID-19) but the clinical course in these patients has not yet been reported. This study aimed to provide a detailed report of the clinical characteristics and outcomes among COVID-19 patients with pre-existing cirrhosis.Methods In this retrospective, multicenter cohort study, we consecutively included all adult inpatients with laboratory-confirmed COVID-19 and pre-existing cirrhosis that had been discharged or had died by 24 March 2020 from 16 designated hospitals in China.Demographic, clinical, laboratory and radiographic findings on admission, treatment, complications during hospitalization and clinical outcomes were collected and compared between survivors and non-survivors.Findings Twenty-one patients were included consecutively in this study, of whom 16 were cured and 5 died in hospital. Seventeen patients had compensated cirrhosis and hepatitis B virus infection was the most common etiology. Lymphocyte and platelet counts were lower, and direct bilirubin levels were higher in patients who died than those who survived (p= 0·040, 0·032, and 0·006, respectively). Acute respiratory distress syndrome and secondary infection were both the most frequently observed complications. Only one patient developed acute on chronic liver failure. Of the 5 non-survivors, all patients developed acute respiratory distress syndrome and 2 patients progressed to multiple organ dysfunction syndrome.Interpretation Lower lymphocyte and platelet counts, and higher direct bilirubin level might represent poor prognostic indicators in SARS-CoV-2-infected patients with pre-existing cirrhosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04329559Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI confirm the availability of all data referred to in the manuscript